Salarius Pharmaceuticals Reveals Pricing for $7 Million Underwritten Public Offering

Public Offering Announcement: Salarius Pharmaceuticals has priced an underwritten public offering to raise approximately $7 million, consisting of shares of common stock and pre-funded warrants, with a combined offering price of $1.50 per share.

Use of Proceeds: The net proceeds from the offering will be used to advance clinical development programs, pay off Decoy Therapeutics' promissory notes, and for general corporate purposes including working capital and research.

Warrants Details: The offering includes Series A and Series B Warrants, both with fixed exercise prices, and the Series A Warrants are exercisable for five years while Series B Warrants are exercisable for one year.

Forward-Looking Statements: The press release contains forward-looking statements regarding the financing and merger with Decoy Therapeutics, highlighting potential risks and uncertainties that could affect the company's future performance.